Company profile: Alphalyse
1.1 - Company Overview
Company description
- Provider of protein chemistry, bioinformatics, and mass spectrometry services for biopharma, biotech companies, and universities, including host cell protein analysis, recombinant protein and monoclonal antibody characterization, advanced therapies and vaccine analysis, LC-MS HCP assay validation and GMP release testing, and GMP-validated MS-based residual enzyme analysis.
Products and services
- LC-MS HCP Assay Validation and GMP Release Testing: Delivers LC-MS-based validation and testing of host cell protein assays under GMP conditions for phase 3 and commercial production release, GMP-compliant
- Host Cell Protein Analysis: Executes quantitative mass spectrometry-based identification and quantification of host cell proteins in biopharmaceutical products to ensure safety and efficacy, MS-based
- Product Characterization: Analyzes recombinant proteins and monoclonal antibodies to optimize process design and ensure drug safety, purity, and potency, bioinformatics-supported
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alphalyse
Eleva Biologics
HQ: Germany
Website
- Description: Provider of novel biological therapies developed with pharmaceutical partners, leveraging a unique moss-based production platform to produce biologics such as antibodies, replacement enzymes, and fusion toxins; has advanced drug candidates into clinical phases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleva Biologics company profile →
PrimeraDx
HQ: United States
Website
- Description: Provider of multiplexed infectious disease assays and Scalable Target Amplification Routine technology for simultaneous quantitative measurement of multiple nucleic acid targets. Offers the ICEPlex system combining PCR and capillary electrophoresis, companion diagnostics, a C. difficile assay, ViraQuant for virus quantification, translational medicine research solutions, and pharma quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PrimeraDx company profile →
ViaCord
HQ: United States
Website
- Description: Provider of women's health biotechnology services, including ViaCord for preserving newborn umbilical cord blood, cord tissue banking, and ViaCyte for cryopreservation of unfertilized eggs, plus newborn genomic offerings such as DNA preservation, celiac and lactose risk testing, a panel analyzing over 270 genes, and whole genome sequencing of 22,000 genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViaCord company profile →
Cevec
HQ: Germany
Website
- Description: Provider of biopharmaceutical production expertise using a unique human cell-based expression system, developing therapeutic proteins and monoclonal antibodies with human glycosylation patterns. CAP-Go enables production of proteins beyond antibodies, including complex glycosylated proteins that are difficult to express in conventional cell lines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cevec company profile →
Araris Biotech
HQ: Switzerland
Website
- Description: Provider of proprietary peptide linker technology for efficient payload attachment without antibody engineering, enabling creation of stable, homogenous, highly soluble antibody-drug conjugates (ADCs) with improved therapeutic efficacy and reduced side effects; also offers ADC development using off-the-shelf antibodies to deliver drugs to cancer cells with improved stability and solubility in a cost-effective manner.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Araris Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alphalyse
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alphalyse
2.2 - Growth funds investing in similar companies to Alphalyse
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alphalyse
4.2 - Public trading comparable groups for Alphalyse
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →